Krystal Biotech Inc (1KRYS)

Currency in EUR
131.70
+2.10(+1.62%)
Closed·

1KRYS Financial Summary

Key Ratios

P/E Ratio35.23
Price/Book4.01
Debt / Equity0.98%
Return on Equity13.9%
Dividend Yield0.00%
EBITDA105.66M
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2016
31/12
2017
31/12
2018
31/12
2019
31/12
2020
31/12
2021
31/12
2022
31/12
2023
31/12
2024
31/12
* In Millions of USD (except for per share items)

Earnings

Latest Release
May 06, 2025
EPS / Forecast
1.20 / --
Revenue / Forecast
88.18M / --
EPS Revisions
Last 90 days

FAQ

What were Krystal Biotech Inc's earnings for the latest quarter?

The Krystal Biotech Inc EPS (TTM) is 4.32. Krystal Biotech Inc reported sales of 88.18, net income of 35.73, and EPS of 1.20 for the latest quarter.

What was Krystal Biotech Inc's net income for the latest quarter?

Krystal Biotech Inc's net income for the latest quarter was 35.73.

How did Krystal Biotech Inc's performance compare year-over-year in the latest quarter?

The company's revenue moved from 91.14 in the previous quarter to 88.18 in the latest quarter, and net income moved from 45.48 to 35.73 compared to the previous quarter.

What is Krystal Biotech Inc's net profit margin on a TTM basis?

Krystal Biotech Inc's trailing twelve months (TTM) net profit margin is 30.69%.

How does Krystal Biotech Inc's debt to equity ratio compare to industry standards?

Krystal Biotech Inc's total debt-to-equity ratio is 0.98%.

What is Krystal Biotech Inc's return on investment on a TTM basis?

Krystal Biotech Inc's trailing twelve months (TTM) return on investment (ROI) is 13.90%.

Did Krystal Biotech Inc gain or lose cash last quarter?

In the latest quarter, Krystal Biotech Inc's net change in cash was -36.10 million.

What were Krystal Biotech Inc's total assets and liabilities in the latest quarter?

As of the latest quarter, Krystal Biotech Inc reported total assets of 1,074.42 million and total liabilities of 79.49 million.

How has Krystal Biotech Inc's total revenue grown this year?

Krystal Biotech Inc's total revenue was 91.14 in the previous quarter and 88.18 in the latest quarter.

What is Krystal Biotech Inc's gross margin on a TTM basis?

Krystal Biotech Inc's trailing twelve months (TTM) gross margin is 93.20%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.